Skip to main content

Table 2 Distributions of BMI, WC and WHR among cases and controls

From: Association between obesity and Barrett’s esophagus in a Japanese population: a hospital-based, cross-sectional study

A. Patients not taking PPIs     
Adiposity measures Controls (%) ESBE ≥ 1 cm (%) P value
BMI, kg/m2 21.8 ± 3.5 (17.2)* 22.9 ± 2.64 (30.4)* 0.11
WC, cm 80.3 ± 10.8 (23.4)** 82.7 ± 8.68 (60.9)** <0.0001
WHR 0.87 ± 0.08 (49.6) 0.90 ± 0.04 (42.9) 0.55
B. Patients regularly taking PPIs     
Adiposity measures Controls (%) ESBE ≥ 1 cm (%) P value
BMI, kg/m2 22.4 ± 3.5 (19.5)* 22.3 ± 3.3 (19.1)* 0.94
WC, cm 80.8 ± 10.2 (29.8)** 81.5 ± 10.1 (36.8)** 0.27
WHR 0.88 ± 0.08 (46.7) 0.88 ± 0.06 (42.3) 0.54
  1. BMI body mass index, WC waist circumference, WHR waist-to-hip ratio, PPI proton pump inhibitor.
  2. ESBE endoscopically suspected Barrett’s esophagus.
  3. P values indicate the comparison in the prevalence between controls and ESBE ≥ 1 cm.
  4. * The prevalence indicates body mass index ≥ 25 kg/m2.
  5. ** The prevalence indicates a large waist circumference defined as ≥ 85 cm for males and ≥ 90 cm for females.
  6. † The prevalence indicates a large waist-to-hip ratio defined as ≥ 0.9 for males and ≥ 0.85 for females.